Michael Drummond is a Respiratory physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4940 Eastern Ave
Baltimore, MD 212242735
Telephone
410-550-0545Registry record last updated 6 Feb 2013.
Clinical trials
- Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
Sponsor: University of North Carolina, Chapel Hill
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments$13,198openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20254 payments$10,672openpaymentsdata.cms.gov ↗
- Verona Pharma, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
64.8%Corticosteroid28.4%Trelegy Ellipta44%Breztri Aerosphere29%Symbicort15%Fluticasone Propionate12%Part D≥26 patientsbeta2-Adrenergic Agonist21.4%Albuterol Sulfate Hfa77%Ventolin Hfa23%Part D≥50 patients+ 5 more classes in this area
Anti-infectives
17.8%Macrolide Antimicrobial16.7%Azithromycin100%Part D≥42 patientsPenicillins with extended spectrum1.2%Amoxicillin-Clavulanate Potass100%Part D<11 patientsMetabolism & gastrointestinal
7.2%Corticosteroid7.2%Prednisone100%Part D≥41 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2010–2016 per NIH RePORTER. The latest:
- Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD
Johns Hopkins University
FY2016$18,973R01HL125432 - Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD
Johns Hopkins University
FY2015$467,913R01HL125432
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”